JAK2 V617F in myeloid disorders: what do we know now, and where are we headed?

Abstract excerpt

Activating tyrosine kinase (TK) mutations disrupt cellular proliferation and survival pathways and are increasingly recognized as a fundamental cause of human cancers. Until very recently, the only TK mutations widely observed in myeloid neoplasia were the BCR/ABL1 fusions characteristic of chronic myeloid leukemia and some acute leukemias, and FLT3 activating mutations in a minority of acute myeloid leukemias....

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to ABL1 gene
• Share to FLT3 gene
• Share to Janus Kinase 2